Companies / HEPACURE-PHARMA
HEPACURE-PHARMA
Company
Hepacure Pharma is developing a first-in-class, dual-acting peptide therapy designed to address two biological drivers of liver fibrosis in MASH.
HEPACURE-PHARMA has 1 investor on file, among them NGT Healthcare II. Its site was last checked 7 Nov 2026: site answers.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
More from NGT Healthcare II
21 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (90%), E-commerce & Marketplaces (5%), Fintech (5%).
See NGT Healthcare II's full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get HEPACURE-PHARMA and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when NGT Healthcare II adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/hepacure-pharma.com/investors
# also
GET /v1/companies/hepacure-pharma.com
GET /v1/companies/hepacure-pharma.com/news